Biosceptre

Biosceptre is a biopharmaceutical company that focuses on chimeric antigen receptor T-cell therapy and immune-oncology treatment. The company is committed to bringing new range of targeted therapies to a broad range of cancer patients.

The company's team comprises of renowned researchers and its work focuses on science from the University of Sydney, Australia. Biosceptre is headquartered in the United Kingdom and has research underway in Sydney and Cambridge, United Kingdom.

Biosceptre's pioneering team discovered the oncology target nfP2X7, which is shown to be present on the cell surface of a wide range of tumour types, including lung, breast, colorectal and prostate. It currently has many nfP2X7-focused programs that are approaching clinical-stage and possess the potential to provide improvements to outcomes for millions of cancer patients globally.

Biosceptre drives innovation and pioneers the future of nfP2X7-targeted oncology therapeutics through the support garnered from its ongoing collaboration with experts and major research institutes.